Introduction
In-hospital and long-term mortality rates vary considerably across the spectrum of patients with acute ST-segment elevation myocardial infarction (STEMI), who receive fibrinolytic therapy. 1 Early and continuous risk stratification is therefore important to enable informed decisions about tailoring of treatment and allocation of clinical resources. Advanced age, lower systolic blood pressure, elevated heart rate, and higher Killip class are important baseline factors associated with increased mortality rates. 2 These and other clinical variables have been combined into the TIMI risk score, which may serve as a tool for the risk assessment at the bedside. 3, 4 In addition, elevated biomarker levels at presentation, including cardiac troponin T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have been shown to provide complementary prognostic information on STEMI. [5] [6] [7] GDF-15 is a member of the transforming growth factor-b (TGF-b) cytokine superfamily. 8 GDF-15 has recently been identified as a gene that is up-regulated in cardiac myocytes by simulated ischaemia, reactive oxygen species, and pro-inflammatory cytokines, suggesting that GDF-15 may be a marker of multiple stress pathways in the heart. 9, 10 Although GDF-15 is not normally expressed in the adult myocardium, GDF-15 is strongly induced in the heart during experimental ischaemia and reperfusion injury. 9 We have recently shown that circulating levels of GDF-15 are elevated and independently related to all-cause mortality in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). 11 To explore whether GDF-15 can provide prognostic information in patients with STEMI, circulating levels of GDF-15 and its relations to clinical characteristics, other biomarkers, and mortality were studied in patients with † These authors have contributed equally.
STEMI from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-2 and ASSENT-plus trials.
Methods Patients and study design
The present investigation is a substudy from the ASSENT-2 and ASSENT-plus trials. ASSENT-2 was a world-wide, multicentre trial comparing tenecteplase with front-loaded alteplase. ASSENT-plus recruited patients in Scandinavia and the USA and compared the efficacy and safety of dalteparin with unfractionated heparin as an adjunct to alteplase. The protocols and main results of the two trials have been published. 12, 13 Inclusion criteria in both trials were symptoms of acute myocardial infarction within 6 h of onset, ST-elevation 0.1 mV in two or more limb leads, 0.2 mV in two or more contiguous precordial leads, or left bundle branch block. Major exclusion criteria included known cerebrovascular disease, uncontrolled hypertension, serum creatinine concentration .150 mmol/L (only in ASSENT-plus), any substantial trauma, or increased risk of severe bleeding. Plasma samples were available from patients enrolled at selected Swedish hospitals in ASSENT-2 (n ¼ 546) and ASSENT-plus (n ¼ 195). The primary endpoint of the present biomarker study was mortality during 1 year, which was evaluated by patient records and telephone contacts. The TIMI risk score, which has been developed as a tool for mortality risk prediction in fibrinolytic-eligible patients with STEMI, was calculated as previously described. 3 Instead of 'history of diabetes, hypertension, or angina', which represents one risk feature in the TIMI score, we used 'history of diabetes or hypertension' because information on previous angina was not available. On the basis of the TIMI score, patients were classified as low risk (0-3 points) or high risk (4-14 points), as described previously. 3 
Blood sampling and laboratory analyses
Venous blood samples were collected into citrate tubes immediately before the start of thrombolytic and anticoagulation treatment and after 90 min. In ASSENT-plus, additional blood samples were obtained after 24 h, 52 h, and 5 days. After centrifugation, plasma samples were stored frozen at 2708C until further analyses. The concentration of GDF-15 was determined by a new immunoradiometric assay, as described earlier.
14 All biomarker measurements were performed by investigators who were unaware of patients' characteristics and outcome. GDF-15 levels at individual time points did not differ significantly between the randomized treatment groups in ASSENT-2 or ASSENT-plus and were therefore combined. Patients were stratified on the basis of the two prespecified GDF-15 cut-off levels, 1200 and 1800 ng/L. As previously shown, 1200 ng/L corresponds to the upper limit of normal in apparently healthy, elderly Swedish individuals.
14 In our previous study in patients with NSTE-ACS, 1200 and 1800 ng/L corresponded to the lower and upper tertile boundaries and allowed for an identification of patients at low (,1200 ng/L), intermediate (between 1200 and 1800 ng/L), or high risk (.1800 ng/L). 11 cTnT was analysed with a third-generation assay on Elecsys 2010 (Roche Diagnostics), with a detection limit of 0.01 mg/L. A concentration of 0.1 mg/L was used for patient stratification based on previous evaluations of cTnT at presentation and prognosis in STEMI 15, 16 ; this cut-off level should not be confused with the cut-off concentration used for diagnosis of myocardial infarction. NT-proBNP was determined with a sandwich immunoassay on Elecsys 2010; the cut-off level of 1000 ng/L was used based on the previous evaluations of NT-proBNP for risk stratification in STEMI. 17 
ST-segment resolution
A subgroup of patients (n ¼ 470) without bundle branch block was monitored for 24 h after presentation by continuous vectorcardiography or by continuous 12-lead ECG for the assessment of ST-segment resolution, as described earlier. 18 Sixty minutes after the start of the recordings, patients were classified according to ST-segment resolution from maximal ST-elevation (,50% ST-segment resolution vs. 50% ST-segment resolution). 18 
Statistical analyses
Data are presented as percentages or median (interquartile range), as appropriate. Spearman's correlation coefficients were calculated to evaluate the relations between the levels of GDF-15 and baseline characteristics. Multiple linear regression was used to evaluate the association of GDF-15 as the dependent variable with other predictors. The Kaplan-Meier method was used to illustrate the timing of events during 1 year in relation to the pre-specified strata of GDF-15 (,1200, 1200-1800 and .1800 ng/L), and statistical assessment was performed using the log-rank test. The differences in proportions in outcome events in the different strata of GDF-15 levels were judged by Fisher's exact test. Simple Cox-regression analysis was used to identify predictors of death during 1 year. All variables were then tested in a multiple Cox-regression analysis. The Wilcoxon signed-rank test was used to compare the changes in GDF-15 within the patient group over time. All P-values are reported two-sided. The alpha-level is 0.05. No adjustments for multiplicity were made, as the results are to be considered exploratory. All data analyses were performed using the SAS 9.1 statistical program.
Results

Baseline characteristics and growth-differentiation factor-15 levels at presentation
The combined patient sample consisted of 221 women (29.8%) and 520 men (70.2%), with a median age of 67 years (interquartile range, 58-74). Baseline characteristics are presented in Table 1 . The median GDF-15 level at presentation was 1635 ng/L (interquartile range, 1164-2309). Two hundred and two patients (27.3%) presented with GDF-15 levels ,1200 ng/L, the upper limit of normal in apparently healthy elderly individuals 14 ; GDF-15 levels were moderately elevated (between 1200 and 1800 ng/L) in 222 patients (30.0%) and highly elevated (.1800 ng/L) in 317 patients (42.8%).
Relations between growth-differentiation factor-15 levels and clinical and biochemical factors
Increasing levels of GDF-15 at presentation were associated with increased age, diabetes, and a history of previous myocardial infarction ( Table 2) . GDF-15 levels were also related to reduced systolic blood pressure, elevated heart rate, Killip class .1, NT-proBNP levels, and a cTnT level at presentation .0.1 mg/L ( Table 2) . By multiple regression analysis that included all patients' characteristics shown in Table 2 and trial (ASSENT-2 vs. ASSENT-plus), and used the natural logarithm of GDF-15 as the dependent variable, GDF-15 was independently associated with age (P , 0.001), male gender (P ¼ 0.027), diabetes (P , 0.001), current smoking (P , 0.001), reduced systolic blood pressure (P , 0.001), elevated heart rate (P , 0.001), Killip class .1 (P ¼ 0.013), NT-proBNP (P , 0.001), and a cTnT level at presentation .0.1 mg/L (P ¼ 0.011). R Growth-differentiation factor-15 levels and mortality GDF-15 levels at presentation were significantly related to the risk of death during 1-year follow-up ( Figure 1) . Patients with GDF-15 levels ,1200 ng/L had a low 1-year mortality rate of 2.1%. Patients with GDF-15 levels between 1200 and 1800 ng/L had an intermediate 1-year mortality rate of 5.0%, whereas those with GDF-15 levels .1800 ng/L had a very high 1-year mortality rate of 14.0% (P , 0.001). Differences in mortality were observed early after the index event ( Figure 1 ) and were highly significant after 30 days ( Table 3) 
Growth-differentiation factor-15 in the context of other markers of increased mortality
Several established markers of increased patient risk, including reduced systolic blood pressure, elevated heart rate, Killip class .1, NT-proBNP, and a cTnT level at presentation .0.1 mg/L, were associated with an increased mortality during 1 year by simple Cox-regression analysis ( Table 4) . Using multiple Cox-regression analysis, only GDF-15 (P ¼ 0.005), reduced systolic blood pressure (P ¼ 0.007), and age [estimated hazard ratio per 5-year increase, 1.35 (95% CI, 1.08-1.70); P ¼ 0.009] emerged as independent predictors of mortality ( Table 4) . Inclusion of peak CK-MB as an additional variable into the multiple Coxregression analysis did not change the overall results (i.e. GDF-15, reduced systolic blood pressure, and age emerged as the only independent predictors). GDF-15 remained independently related to mortality when including in-hospital Table 2 Patients' characteristics according to growth-differentiation factor-15 levels at presentation b-blocker and ACE-inhibitor therapy as additional variables into the multiple Cox-regression analysis (data on in-hospital treatment were available only in ASSENT-2).
Prognostic utility of growth-differentiation factor-15 in different patient subgroups
The prognostic utility of GDF-15 was explored across the clinical spectrum of patients by using the pre-specified GDF-15 cut-off level of 1800 ng/L. As shown in Figure 2 , a GDF-15 level .1800 ng/L was associated with a significantly increased risk of death in most investigated subgroups.
Growth-differentiation factor-15 adds prognostic information to cardiac troponin T, N-terminal pro-B-type natriuretic peptide, and the TIMI risk score
A GDF-15 level .1800 ng/L was associated with a 2.2-fold and a 4.8-fold higher risk of death during 1 year in patients with an NT-proBNP level 1000 or .1000 ng/L, respectively ( Figure 2) . Similarly, a GDF-15 level .1800 ng/L was associated with a 3.1-fold and a 5.0-fold higher risk of death during 1 year in patients presenting with a cTnT level 0.1 or .0.1 mg/L, respectively. Moreover, a GDF-15 level .1800 ng/L was associated with a 4.9-fold higher risk of death during 1 year in patients with a TIMI score .3. Patients presenting with a TIMI score 0-3 had a low 1-year mortality rate of 3.0% (13 deaths in 431 patients), and GDF-15 did not add significant prognostic information in the low-risk subgroup (Figure 2 ).
Temporal evolution of growth-differentiation factor-15 levels in ST-segment elevation myocardial infarction
After presentation, GDF-15 levels remained elevated for at least 5 days (Figure 3 ). In the combined patient population, 72.7, 88.2, 76.0, 76.8, and 69.0% of the patients had GDF-15 levels above the upper limit of normal (1200 ng/L) at presentation, after 90 min, 24 h, 52 h, and after 5 days, respectively. GDF-15 levels measured 90 min after the start of randomized treatment were significantly higher when compared with the values at presentation; the levels increased from 1661 ng/L (interquartile range, 1187-2367) to 2179 ng/L (1470-3262) in ASSENT-2 and from 1563 ng/L (1105-2148) to 3009 ng/L (1789-4554) in ASSENT-plus ( Figure 3) . As shown in ASSENT-plus, GDF-15 levels at 24 and 52 h were still slightly higher when compared with the values at presentation (Figure 3 ). To explore whether the peak in circulating GDF-15 concentrations at 90 min was related to successful reperfusion, the rise in GDF-15 from baseline to 90 min was re-evaluated in 462 patients, in whom paired baseline and 90 min plasma samples and continuous vectorcardiography or 12-lead ECG recordings were available. However, GDF-15 levels increased to a similar extent after 90 min in patients with or without ST-segment resolution 50% at 60 min (P ¼ 0.28), arguing against a reperfusion-induced rise in circulating GDF-15 levels.
GDF-15 levels at 90 min (n ¼ 711) provided significant prognostic information, with 1-year mortality rates of 1.2 and 8.4% in patients with GDF-15 levels ,1200 or 1200 ng/L, respectively (P ¼ 0.014). Similar trends were observed at 24 h, 52 h, or after 5 days, although the numbers of available samples at these later time points were too small to allow definitive conclusions (data not shown).
Discussion
This study demonstrates, for the first time, that GDF-15 is a biomarker of raised mortality in patients with acute STEMI that adds independent prognostic information to established clinical and biochemical markers. Our data show that patients who present with a GDF-15 concentration within the normal range (,1200 ng/L) have a rather good prognosis with a 1-year mortality rate of 2.1%. Conversely, elevated levels of GDF-15 are indicative of a worse prognosis, with 1-year mortality rates of 5.0 and 14.0% in patients with moderately elevated (between 1200 and 1800 ng/L) or markedly elevated levels of GDF-15 (.1800 ng/L), respectively. Mortality curves showed a very early separation, indicating that measurement of GDF-15 may enable risk stratification Patients with STEMI (n ¼ 730) were stratified according to their GDF-15 levels at presentation and followed up to 1 year. Per cent mortality is shown (patient numbers in parentheses).
P-values were calculated with Fisher's exact test. Figure 1 Cumulative probability of death according to levels of growthdifferentiation factor-15 at presentation in 730 patients with ST-segment elevation myocardial infarction enrolled in ASSENT-2 or ASSENT-plus (P , 0.001 by log-rank test).
for a time window when important management decisions are made. Data on the cause of death were not available in our patient population. However, as previous investigations have shown that 85% of the mortality during the first year after STEMI is due to ischaemic heart disease events, 19 it can safely be concluded that the increase in the mortality in patients with elevated levels of GDF-15 in our study is related to an increase in the cardiovascular mortality. Although our data suggest that 1200 and 1800 ng/L are useful cut-points for risk stratification, this does not imply that mortality risk is homogeneous within each of these three strata. In fact, there appeared to be a continuous relationship between the GDF-15 level and mortality risk as shown by the multiple Cox-regression analysis.
GDF-15 provided prognostic information on clinically relevant patient subgroups defined according to age, gender, delay time, cardiovascular risk factors, haemodynamic status, and TIMI risk score at presentation. Highlighting an even broader role for GDF-15 as a prognosticator in acute coronary syndrome, we have recently identified GDF-15 as an independent prognostic marker also in patients with NSTE-ACS. 11 Patients with STEMI in the present study and patients with NSTE-ACS in our previous report presented with similar levels of GDF-15 (the median GDF-15 level was 13% higher in STEMI when compared with NSTE-ACS).
11 Accordingly, the present study verified prospectively the same cut-off levels as being useful for risk stratification in both ST-elevation and non-ST-elevation ACS.
Troponin levels on admission are often used in clinical practice for risk assessment in patients with STEMI, as patients presenting already with elevated levels of troponin are known to have a 2-3-fold higher risk of death during follow-up. 6, 7 As shown in the present study, risk stratification based on cTnT on admission was significantly improved by adding GDF-15. In STEMI, cTnT levels are related to symptom duration, and most patients have elevated levels after 6 h. 6, 20 In contrast, GDF-15 levels at presentation were not related to symptom duration (delay time) in the present study. Moreover, GDF-15 carried similar prognostic information when determined at presentation, 90 min after admission, and possibly even at later time points. This parallels our findings in NSTE-ACS, in which GDF-15 levels determined on admission and up to 72 h later provided similar prognostic information.
11 NT-proBNP (or BNP) levels at presentation are related to long-term mortality in STEMI. 5, 7, [21] [22] [23] As shown in the present study, combination of NT-proBNP with GDF-15 allowed us to identify patients with NT-proBNP levels .1000 ng/L at very high or relatively low risk. As the information provided by GDF-15 was independent of cTnT and NT-proBNP on admission, and also independent of peak CK-MB, combination of GDF-15 with these established biomarkers may allow for a more refined risk stratification.
Among the three biomarkers examined here (cTnT, NT-proBNP, and GDF-15), GDF-15 emerged as the only marker that was independently related to mortality by the multiple Cox-regression analysis. Although our data also indicate that GDF-15 adds prognostic information to cTnT and NT-proBNP, it should be pointed out that cTnT and NT-proBNP appeared to provide better prognostic information when compared with GDF-15, when the three markers were interpreted individually (as evidenced by the simple Cox-regression analysis).
GDF-15 levels at presentation were independently related to age, male gender, diabetes, current smoking, reduced systolic blood pressure, elevated heart rate, Killip class .1, and the levels of NT-proBNP and cTnT, suggesting that GDF-15 carries at least some of the prognostic information contained in these clinical and biochemical markers of more severe cardiovascular disease and/or poor prognosis in patients with STEMI. However, these factors explained only part of the variation in the GDF-15 levels (R 2 value, 0.32), indicating that additional, as yet undefined, factors have an impact on the GDF-15 level. In experimental studies, cardiac GDF-15 expression levels are controlled by oxidative/nitrosative stress and pro-inflammatory cytokinemediated pathways. 9 Circulating levels of GDF-15 may therefore provide insight into a distinct pathophysiological process in patients with STEMI.
Circulating levels of GDF-15 remained increased for at least 5 days after presentation in our study, which is consistent with studies in mice showing that GDF-15 expression levels in the heart remain elevated for at least 1 week after an episode of myocardial ischaemia. 9 There was a transient peak in GDF-15 levels 90 min after the start of randomized treatment, which was observed in patients with or without successful reperfusion as judged by ST-segment Hazard ratios refer to 1 SD in the natural logarithmic scale.
resolution at 60 min. 24, 25 Washout of GDF-15 from the reperfused myocardium is therefore unlikely to explain this peak. The early rise in circulating GDF-15 levels may be related to increased synthesis of GDF-15 during the early hours of a myocardial infarction, or, possibly, to thrombolytic therapy and plasmin-mediated cleavage and release of GDF-15 from extracellular proGDF-15 stores, a mechanism that is operative in the processing of TGF-b. 26, 27 In any case, measurement of GDF-15 levels at 90 min provided prognostic information, similar to the levels at presentation.
In conclusion, GDF-15 is a new and independent biomarker of the risk of death in patients with STEMI. As this is the first presentation of results on the prognostic importance of GDF-15 in STEMI, these results need to be further explored in forthcoming studies before considering implementation in clinical practice. These studies need to define the prognostic value and clinical utility of GDF-15 when compared with more established biomarkers, such as the cardiac troponins and NT-proBNP. It will be especially important to see whether GDF-15 levels can help with patient management decisions. Figure 2 Risk of death during 1 year associated with a growth-differentiation factor-15 level .1800 ng/L at presentation in subgroups of 730 patients with ST-segment elevation myocardial infarction from ASSENT-2 or ASSENT-plus. The number of patients, mortality rates [% (n)], estimated hazard ratios, and 95% confidence interval are shown. P-values refer to the comparison between the event rates in patients with growth-differentiation factor-15 levels .1800 vs. 1800 ng/L in each stratum. Data have been adjusted for trial (ASSENT-2 vs. ASSENT-plus). For analyses according to age, delay time, systolic blood pressure (BP), and heart rate, the median values of the entire study sample were used to create subgroups of comparable size. *Hazard ratios could not be calculated in the ASSENT-plus cohort (there were zero deaths in 121 patients with GDF-15 levels 1800 ng/L and eight deaths in 74 patients with GDF-15 levels .1800 ng/L) and in diabetic patients (there were zero deaths in 29 patients with GDF-15 levels 1800 ng/L and nine deaths in 52 patients with GDF-15 levels .1800 ng/L).
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